Trends in the practice of molecular cytopathology in response to the COVID pandemic
Graphical Abstract
In the recent pandemic emergency caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), most activities in many areas of medicine have undergone a remarkable reduction. The health emergency has underlined the evolving role of cytopathology that is increasingly playing a remarkable role in providing oncologists and other physicians with timely information on personalised modern treatment of cancer diagnosed by cytological means.
CONFLICT OF INTEREST STATEMENT
Giancarlo Troncone reports personal fees (as speaker bureau or advisor) from Roche, MSD, Pfizer, Boehringer Ingelheim, Eli Lilly, BMS, GSK, Menarini, AstraZeneca, Amgen, and Bayer, unrelated to the current work.
Open Research
DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no new data were created or analysed in this study.
